Catalyst Event
Bristol-Myers Squibb Co (BMY) · Other
From Akros U.S. High Dividend 20 Index (AUHDIV20)
3/20/2026, 12:00:00 AM
Expanded approvals for Opdivo (nivolumab) for new indications on 2026-03-20. This blockbuster drug expansion is estimated to have a moderate impact on revenue (Medium importance) expected.
Korean Translation
2026-03-20에 옵디보(니볼루맙)의 신규 적응증 확대 승인이 예정됨. 블록버스터 약물의 적응증 확대로 매출에 중간 정도의 영향이 예상됨.
Related Recent Events
Target Corp (TGT) · Earnings Release
Q1 2026 earnings release scheduled for 2026-05-20 scheduled.
5/20/2026, 12:00:00 AM
ONEOK Inc (OKE) · Other
2026 Annual Meeting of Shareholders, which is expected to have low impact as a standard meeting, is scheduled.
5/20/2026, 12:00:00 AM
Dominion Energy Inc (D) · Other
Annual Meeting of Shareholders scheduled for 2026-05-05. Shareholders will vote on director elections, executive compensation, and shareholder proposals. This routine meeting is estimated to have a 1% impact on the stock price scheduled.
5/5/2026, 12:00:00 AM
ONEOK Inc (OKE) · Earnings Release
Q1 2026 earnings release, which is expected to have low impact as a routine reporting event, is scheduled.
5/5/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
First quarter 2026 financial results and conference call scheduled for 2026-04-30. Routine earnings announcements typically result in minor price fluctuations (Low importance) scheduled.
4/30/2026, 12:00:00 AM
United Parcel Service Inc (UPS) · Earnings Release
Q1 2026 earnings release scheduled. Medium importance is assigned as earnings releases typically cause price volatility exceeding 5%.
4/28/2026, 12:00:00 AM